SAN ANTONIO– bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive diagnostics for lung cancer and other lung diseases, has released three new case studies demonstrating the clinical impact of its CyPath Lung test.
The reports include one patient whose lung cancer was detected at Stage 1A — its earliest and potentially curative stage — and two patients who were spared invasive procedures after negative results suggested a lower risk of malignancy.
“These three new cases, provided by a Texas pulmonologist who has been using CyPath Lung for more than a year, reflect what we’re hearing from many physicians – CyPath Lung enhances clinical decision-making by personalizing care and playing a critical role in refining the diagnostic pathway,” said Dr. Gordon Downie, Chief Medical Officer of bioAffinity Technologies. “We believe CyPath Lung can be a transformative tool in the lung cancer diagnostic pathway, especially when imaging results are inconclusive. A positive CyPath Lung result can lead to earlier diagnosis and treatment, and a negative result can spare patients from unnecessary invasive procedures.”
One case involved a 68-year-old smoker referred to as “Samuel,” whose CT scan showed a suspicious lesion but who was reluctant to undergo a biopsy. A positive CyPath Lung result shifted the clinical picture and persuaded him to proceed. Pathology confirmed Stage 1A lung cancer, allowing for timely and potentially life-saving treatment.
In another case, “David,” a patient whose low-dose CT revealed a nodule and enlarged lymph nodes, faced the possibility of a biopsy. However, a negative CyPath Lung result suggested a low likelihood of cancer. He opted instead for ongoing monitoring with serial CT scans in accordance with his care team’s protocol.
A third case described a patient named “Lisa,” who had end-stage COPD and a history of lung cancer. When a new pulmonary nodule was discovered, her doctors were hesitant to pursue a risky biopsy. A positive CyPath Lung result gave her team confidence to proceed with radiation therapy without biopsy, and the lesion has remained stable a year later.
Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies, said the growing collection of real-world results is affirming the test’s clinical value. “As more and more physicians use CyPath Lung, it is both gratifying and humbling to see how our test can help patients and their physicians navigate the diagnostic uncertainty that often surrounds the increasing number of indeterminate, small pulmonary nodules found by imaging.”
